The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.